2026-01-07 - Analysis Report
Okay, here's a comprehensive analysis of Eli Lilly (LLY) based on the provided data, broken down into the requested sections:

**0) Report in English (Simple Numbers First, then Analysis)**

**1) Return Rate Comparison and Analysis:**

*   **Company Overview:** Eli Lilly and Co. is a global pharmaceutical company discovering, developing, and marketing human health products.
*   **LLY Cumulative Return:** 281.68%
*   **VOO (S&P 500) Cumulative Return:** 91.00%
*   **Divergence:**
    *   Current Divergence: 190.7
    *   Relative Divergence: 83.9

**Analysis:** Eli Lilly has significantly outperformed the S&P 500. The divergence shows a substantial lead in cumulative returns. The relative divergence of 83.9 indicates that the current divergence is high compared to its historical range, suggesting that LLY's outperformance is currently strong relative to its past performance compared to the S&P 500.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD     | Alpha   | Beta  | Cap(B) |
|------------|---------|---------|---------|-------|--------|
| 2016-2018  | 37.0%   | 14.3%   | 33.0%   | 0.7   | 102.2  |
| 2017-2019  | 36.0%   | 14.7%   | 19.0%   | 0.7   | 116.0  |
| 2018-2020  | 30.0%   | 20.9%   | 10.0%   | 0.7   | 149.1  |
| 2019-2021  | 49.0%   | 20.9%   | 5.0%    | 0.7   | 243.9  |
| 2020-2022  | 59.0%   | 20.9%   | 60.0%   | 0.7   | 323.0  |
| 2021-2023  | 116.0%  | 18.0%   | 115.0%  | 0.5   | 514.7  |
| 2022-2024  | 123.0%  | 27.0%   | 104.0%  | 0.6   | 681.6  |
| 2023-2025  | 183.0%  | 29.9%   | 121.0%  | 0.7   | 948.9  |

**Analysis:**

*   **CAGR:** Compounded Annual Growth Rate has been consistently strong and has increased significantly, indicating accelerating growth.
*   **MDD:** Maximum Drawdown is relatively consistent, suggesting moderate risk management, but has increased in the most recent period.
*   **Alpha:** Alpha is consistently high, particularly in recent years, which confirms its strong outperformance relative to the market (risk-adjusted return).
*   **Beta:** Beta is consistently below 1, meaning the stock is less volatile than the market (S&P 500).
*   **Cap(B):** The market capitalization in billions has grown significantly, indicating a substantial increase in the company's value.

**2) Recent Stock Price Fluctuations:**

*   **Current Close:** 1080.36
*   **Last-market:**
    *   Price: 1064.04
    *   Previous Close: 1041.51
    *   Change: 2.16
*   **5-day SMA:** 1078.25
*   **20-day SMA:** 1046.91
*   **60-day SMA:** 968.37

**Analysis:** The stock price is above all three moving averages, indicating an upward trend. The 5-day SMA is higher than the 20-day SMA, which is higher than the 60-day SMA, further reinforcing this bullish signal. The recent market data indicates positive change, but should be considered relative to the overall trend and news.

**3) RSI, PPO, and Expected Return Analysis:**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment)
*   **RSI:** 76.97 (Overbought)
*   **PPO:** -0.156 (Bearish signal on momentum)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90)
*   **Recent (20 days) Relative Divergence Change:** 0.6 (+) (Short-term Increase)
*   **Expected Return (%):** 47.3%

**Analysis:** The MRI suggests a medium level of investment recommendation.  The RSI is in overbought territory, which *could* suggest a potential pullback.  The PPO indicator is a bearish signal on momentum. Despite the high RSI, the hybrid signal suggests a strong buy recommendation due to the MRI, indicating that despite short-term potential for correction, long-term prospects are favorable. The recent increase in relative divergence is positive. The high expected return suggests strong confidence in LLY's future performance over a longer time horizon.

**4) Recent News & Significant Events:**

*   **Eli Lilly Stock (LLY) Falls 4% as Rival Novo Nordisk Begins Selling Obesity Pill in U.S.:** This is a negative short-term catalyst, creating potential competitive pressure.
*   **Is It Time to Dump Your Shares of Eli Lilly?:** Suggests some uncertainty or concern about the stock's valuation or near-term prospects.
*   **Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note:** Highlights a potential underperformance relative to the broader market on a specific day.
*   **Eli Lilly Lags In The Weight-Loss Pill War. But It Has A Plan:** This suggests the company is aware of competitive challenges and is developing strategies to address them.
*   **Ventyx Biosciences stock surges after Eli Lilly acquisition talks:** Implies potential acquisition activity, which can be a positive catalyst.
*   **3 Top Ranked Stocks to Buy for 2026 (LLY, WFRD, PGY):**  Positive analyst outlook, reinforcing bullish sentiment.

**Analysis:** The news is mixed.  The competition in the obesity drug market is a concern, and some articles question the stock's current valuation. However, the potential acquisition and overall positive analyst rankings provide offsetting positive signals. The market seems sensitive to news related to the weight-loss drug market competition.

**4-2) Analyst Opinions:**

*   **Consensus:** Buy (Mean: 1.70)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 1098.04 / 1500.00 / 770.00

**Analysis:** Strong analyst support with a "Buy" consensus. The average target price is slightly above the current price, suggesting some potential upside. The high target price indicates some analysts are very bullish on the stock. No recent rating changes were provided, so we can't assess any shifts in analyst sentiment.

**5) Recent Earnings Analysis:**

| 날짜       | EPS    | 매출       |
|------------|--------|------------|
| 2025-10-30 | 6.22   | 17.60 B$   |
| 2025-08-07 | 6.30   | 15.56 B$   |
| 2025-05-01 | 3.07   | 12.73 B$   |
| 2024-10-30 | 1.08   | 11.44 B$   |
| 2025-10-30 | 1.08   | 11.44 B$   |

**Analysis:**  Both EPS (Earnings Per Share) and Revenue have generally been increasing over the reported quarters.  There seems to be an extra, duplicate listing of the data from 2024-10-30, but in general it suggests a strong trajectory of profitability and growth.

**6) Financial Information:**

**Revenue and Profitability:**

| Quarter      | Revenue    | Profit Margin |
|--------------|------------|----------------|
| 2025-09-30   | $17.60B    | 82.91%          |
| 2025-06-30   | $15.56B    | 84.27%          |
| 2025-03-31   | $12.73B    | 82.53%          |
| 2024-12-31   | $13.53B    | 82.24%          |
| 2024-09-30   | $11.44B    | 81.02%          |

**Capital and Profitability:**

| Quarter      | Equity     | ROE     |
|--------------|------------|---------|
| 2025-09-30   | $23.79B    | 23.46%  |
| 2025-06-30   | $18.27B    | 30.98%  |
| 2025-03-31   | $15.76B    | 17.50%  |
| 2024-12-31   | $14.19B    | 31.07%  |
| 2024-09-30   | $14.24B    | 6.81%   |

**Analysis:** Revenue is consistently growing. Profit margins are exceptionally high and stable, indicating strong pricing power or cost management. Equity is increasing, which is generally a positive sign for the company's financial health. ROE (Return on Equity) fluctuates, with a spike in some quarters, but is generally healthy, indicating efficient use of shareholder equity to generate profits.

**7) Comprehensive Analysis (Summary):**

Eli Lilly (LLY) has demonstrated significant outperformance compared to the S&P 500, driven by strong revenue and earnings growth, coupled with very high profit margins.  The stock exhibits lower volatility than the market. Analyst sentiment is strongly positive, with a consensus "Buy" rating and potential upside according to target prices.

However, there are some potential risks:

*   **Competition:** Increasing competition in the weight-loss drug market is a key concern, reflected in recent news.
*   **Valuation:** The high RSI indicates overbought conditions, and some analysts question the current valuation, which could lead to a pullback.
*   **Short-Term Negative News:** The stock is sensitive to negative news in the weight-loss market space.

**Overall Recommendation:**

Based on this data, Eli Lilly appears to be a fundamentally strong company with excellent growth prospects. While the short-term overbought conditions and competitive pressures warrant caution, the long-term outlook remains positive. The "Medium Investment" recommendation from the MRI seems appropriate, suggesting that investors should consider the risks and potential rewards carefully before making a decision. The hybrid signal supports a buy recommendation.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.